NCT06153901

Brief Summary

Endoscopic full-thickness plication (EFTP) of cardia/fundus has been shown effective in treating GERD patients. However, EFTP requires proprietary equipment that are not available in many countries. Here, we designed a metal clip and endoloop mediated cardioplication (ECLC) procedure to achieve EFTP.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2023

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 22, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 1, 2023

Completed
9 days until next milestone

Study Start

First participant enrolled

December 10, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2024

Completed
Last Updated

December 1, 2023

Status Verified

November 1, 2023

Enrollment Period

1 year

First QC Date

November 22, 2023

Last Update Submit

November 22, 2023

Conditions

Keywords

Gastroesophageal Reflux DiseaseEndoscopy Upper GI Tractanti-refluxEndoscopic therapy

Outcome Measures

Primary Outcomes (1)

  • The total score of the GERD-HRQL questionnaire

    Questionnaire (GERD-HRQL) : Total Score: Calculated by summing the individual scores toquestions 1-15 Greatest possible score ( worst symptoms)= 75 Lowest possible score ( no symptoms)= 0 Heartburn Score: Calculated by summing the individual scores to questions 1-6 . Worst heartburn symptoms = 30 No heartburn symptoms= 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate heartburn elimination. Regurgitation Score: Calculated by summing the individual scores to questions10-15. Worst regurgitation symptoms = 30 No regurgitation symptoms = 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate regurgitation elimination.

    at 3 month follow- up

Secondary Outcomes (6)

  • PPI usage

    at 3, 6 and 12 month follow- up

  • Total score of GERD GerdQ questionnaire

    at 3 month follow- up

  • Total score of GERD GerdQ and GERD HRQL questionnaires

    at 6 and 12 month follow- up

  • Esophageal acid reflux and DeMeester score

    at 3, 6, and 12 months follow- up

  • Healing status of reflux esophagitis and damaged mucosa

    at 3, 6, and 12 months

  • +1 more secondary outcomes

Study Arms (1)

endoloop mediated cardioplication (ECLC)

EXPERIMENTAL

The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.

Procedure: endoloop mediated cardioplication (ECLC) procedure

Interventions

The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.

endoloop mediated cardioplication (ECLC)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-60 years old
  • hiatal hernia ≤ 3cm
  • Sliding hernia ≤ 3cm
  • Classic reflux symptoms (heartburn, reflux) lasting for more than 6 months
  • Daily PPIs ≥ 6 months
  • Esophagitis (Los Angeles grade) Grade A, B, and C
  • Gastroesophageal valve I-III grade (Hill grade)
  • Pathological esophageal acid exposure (percentage of time with 24-hour esophageal PH\<4 \<4.2%)
  • Normal or near normal esophageal movement (through manometry or impedance)
  • The lower esophageal sphincter pressure (LESP) is between 5-15mmHg
  • DeMeester score ≥ 14.7 or total reflux episodes\>73
  • Patients who sign an informed consent form and voluntarily accept surgical expenses.

You may not qualify if:

  • BMI\>35kg/m2
  • ASA \>II
  • Barrett's esophagus
  • Hill IV level
  • Large esophageal hiatal hernia\>3cm
  • Esophagitis (Los Angeles grade) Grade D
  • Peptic ulcer
  • Primary esophageal motility disorders such as achalasia
  • Previous esophageal or gastric surgery
  • Uncontrolled systemic diseases
  • Pregnancy or planned pregnancy within 1 year
  • Have a history of cervical fusion surgery, esophageal diverticulum, scleroderma or dermatomyositis, eosinophilic esophagitis, liver cirrhosis or coagulation dysfunction, immune system diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Gastroesophageal Reflux

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

November 22, 2023

First Posted

December 1, 2023

Study Start

December 10, 2023

Primary Completion

December 10, 2024

Study Completion

December 10, 2024

Last Updated

December 1, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share